OmniPod (PODD): Debts to Book Capitalization

Brandmark of Insulet Corp (PODD)

Insulet Corporation (PODD) revenue growth is driven by the sale of innovative Omnipod tubeless pumps. The ratio of attracted funds to book capitalization confirms the trend's stability, with the parameter marked at 0.64. Business scalability is supported by consistent demand for consumables. Stable development is guaranteed by a strong team of engineers and developers who effectively maintain the company's core R&D potential.

PODD - Insulet Inc. Debts to Net Assets over the range 07/04/2022 - 10/27/2026

Metric breakdowns and analytics for Insulet Corp (PODD)

- price and consensus price forecast:
Stock Price Insulet Corporation|PODD - Average Forecast Price
- market capitalization data:
Market Capitalization Insulet Inc.|PODD - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Insulet|PODD - Book Valuation of Business|Market Capitalization to Book Value Ratio insulet.com|PODD - Company Total Assets
- debt and liquidity data:
Debt to Equity Insulet Corporation|PODD - Long-Term Debt to Equity|Short-Term Debt to Capital OmniPod|PODD - Company Total Debt Obligations|Debt to Book Value Insulet Inc.
Analysis of all company metrics:Insulet Corporation
Original product of Insulet Corp

Investors use this metric to assess the sustainability of financial leverage and the risk of cash flow gaps amid changing interest rates. The ratio of total liabilities to the book value of equity on the debt-to-equity chart reflects the asset value of Insulet Corporation (PODD), including high-tech plants in the US and China that require constant capital expenditures for sterility and automation.

Competitors of Insulet Corporation

BSX: Debts to Book Capitalization|Debts to Book Value edwards.com EW|RMD: Debts to Book Capitalization|ZBH - Debt to Book Value|CooperVision - Debts to Book Capitalization|Align Corp (ALGN) - Debts to Net Assets|GMED (Globus Medical, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization TMDX|Debt to Book Capitalization Ratio Alphatec (ATEC)|Debt to Book Capitalization Ratio CryoLife (AORT)|Debts to Book Capitalization ENOV|IART - Debts to Net Assets|Debt to Book Value Establishment Labs|BBNX - Debts to Book Capitalization Ratio|Debts to Book Capitalization IRMD|Embecta Corp (EMBC) - Debts to Book Value|Debts to Book Capitalization Tandem Diabetes (TNDM)|Debt to Book Value Ratio Axogen Surgical (AXGN)|SI-BONE, Inc. (SIBN) - Debt to Book Value|Debt to Net Assets Ratio OFIX (orthofix.com)|Bioventus - Debt to Book Capitalization Ratio|Debt to Book Value OrthoPediatrics Corp KIDS|TMCI (Treace Medical) - Debts to Book Capitalization|SRTA - Debts to Book Value|Debts to Book Capitalization Carlsmed Inc|rxsight.com (RXST) - Debt to Book Value Ratio|CLPT: Debts to Book Capitalization|Debts to Net Assets Stereotaxis Inc|Debts to Book Capitalization STIM (NeuroStar)|Debt to Book Value Sight Sciences Inc (SGHT)|Debts to Book Capitalization OBIO (Orchestra BioMed, Inc.)|Anika Therapeutics Inc. - Debts to Book Capitalization|NSPR - Debt to Book Capitalization Ratio|Jin Medical International (ZJYL) - Debt to Book Capitalization Ratio|Debt to Book Value vivani.com VANI|Xtant Medical (XTNT) - Debt to Net Assets Ratio|Debts to Book Capitalization NMTC (NeuroOne Medical Technologies)|Debts to Book Value MODD|MYO: Debt to Book Capitalization Ratio|Debt to Net Assets Envoy Medical Inc. COCH|Debt to Book Value VVOS (Vivos Therapeutics, Inc)|Debts to Book Capitalization enVVeno Corp NVNO|Debts to Book Capitalization SINT (SINTX Technologies)|TNON: Debts to Net Assets|Debt to Book Capitalization Ratio Lifeward (LFWD)|AMIX (Autonomix Medical) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio IVF|Debt to Book Value Bone Biologics Inc|Axonics, Inc. - Debts to Book Capitalization|Debts to Book Value BIOL (biolase.com)|DYNT - Debt to Book Capitalization Ratio|FNA - Debt to Book Value Ratio|Debt to Book Value INVO Bio INVO